Saol CRL Suggests Gap Between US FDA Rare Disease Flexibility Promises And Outcomes

 
• By Bridget Silverman
  
Saol Therapeutics is hoping to find a safe harbor for SL1009 after an FDA complete response letter calls for a new trial. (Shutterstock)

More from Complete Response Letters

More from Product Reviews